Seibel M M, McArdle C, Smith D, Taymor M L
Fertil Steril. 1985 May;43(5):703-8. doi: 10.1016/s0015-0282(16)48551-1.
In patients with polycystic ovarian disease (PCOD) ovulation was induced with a combination of human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG) or with urinary follicle-stimulating hormone (uFSH; Metrodin, Serono Laboratories, Inc., Randolph, MA) alone. hMG/hCG and uFSH resulted in comparable rates of ovulation and conception in patients with PCOD. The incidence of hyperstimulation and the potential for multiple births appeared lower with uFSH. The fact that endogenous ovulation did not occur in hMG patients who had hCG withheld or in 3 of the 11 uFSH patients who had preovulatory levels of estradiol and follicles greater than 15 mm may imply that these similarly derived gonadotropins in some instances block endogenous ovulation.
在多囊卵巢疾病（PCOD）患者中，采用人绝经期促性腺激素（hMG）和人绒毛膜促性腺激素（hCG）联合使用或单独使用尿促卵泡素（uFSH；Metrodin，雪兰诺实验室公司，马萨诸塞州伦道夫）诱导排卵。hMG/hCG和uFSH在PCOD患者中导致相似的排卵率和受孕率。uFSH的过度刺激发生率和多胎妊娠可能性似乎较低。在hCG withheld的hMG患者或11例uFSH患者中有3例在排卵前雌二醇水平和卵泡大于15mm时未发生内源性排卵，这一事实可能意味着这些来源相似的促性腺激素在某些情况下会阻断内源性排卵。
